粉防己碱对自发性高血压大鼠血管平滑肌细胞增殖及对PDGF-B, bFGF和相关癌基因表达的影响

用［³H］胸腺嘧啶核苷 (［³H］TdR)参入法, 电镜, 免疫组化, 原位杂交方法, 在自发性高血压大鼠(SHR)观察了粉防己碱(Tet, 0.03 μmol·kg^-1·d^-1×8周 ig)对血管平滑肌细胞(VSMC)增殖的作用及对生长因子PDGF-B, bFGF的抗原表达及其相关癌基因c-sis, c-myc mRNA表达的影响. 结果发现: Tet在降低SHR血压(P<0.01)同时, 能减少VSMC的线粒体,粗面内质网和［³H］TdR参入量(P<0.01), 并能逆转VSMC增殖时PDGF-B, bFGF抗原(P<0.05)及c-sis, c- myc mRNA的表达增强. 提示: Tet抑制SHR的VSMC增殖与生长因子及癌基因调控的分子生物学机制有关.     

卡托普利对自发性高血压大鼠血管平滑肌细胞增殖及癌基因和 …

目的：观察卡托普利（Ｃａｐ）的自发性高血压大鼠（ＳＨＲ）血管平滑肌细胞（ＶＳＭＣ）增殖的作用及对原癌基因及抑癌基因的影响。方法：氚－胸腺嘧啶核苷（＾３Ｈ－ＴｄＲ）参入，电镜，原位杂交及Ｎｏｒｔｈｅｒｎ ｂｌｏｔ杂交。结果：Ｃａｐ在降低ＳＨＲ血压同时，能减少ＶＳＭＣ的线粒体，粗面内质网及＾３Ｈ－Ｔｄ参入量（Ｐ〈０．０１），并有逆转ｃ－ｆｏｓ，ｃ－ｍｙｃ，ｃ－ｓｉｓ原癌基因ｍＲＮＡ表达增强（Ｐ〈０．０     

叶酸抑制同型半胱氨酸诱导大鼠血管平滑肌细胞增殖的研究

目的探讨叶酸抑制同型半胱氨酸致大鼠血管平滑肌细胞增殖的研究。方法培养大鼠胸主动脉血管平滑肌细胞(VSMC),流式细胞仪检测VSMC周期,[3H]TdR参入测定VSMC的DNA合成。结果同型半胱氨酸以剂量依赖关系使VSMC周期中的G0/G1期细胞比例明显减少,S期细胞比例显著增多,增加VSMC的[3H]TdR参入。叶酸可明显抑制同型半胱氨酸诱导的作用。结论同型半胱氨酸能诱导VSMC增殖,叶酸能抑制同型半胱氨酸诱导的VSMC增殖。     

醋柳黄酮及其单体对培养自发性高血压大鼠血管平滑肌细胞c-myc表达的影响

探讨醋柳黄酮（TFH）及其单体槲皮素（Que)、异鼠李素（Isor)对培养自发性高血压大鼠（SHR）血平滑肌细胞（VSMC）原癌基因c-myc表达的影响。结果显示,药物在一定浓度下能有效抑制SHR、VSMC、c-myc、mRNA表达和c-myc蛋白合成,提示醋柳黄酮及其单体的降压机制可能涉及原癌基因c-myc的调节环节。     

1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙氨基)丙烷盐酸盐对内皮素促血管平滑肌细胞增殖及癌基因表达的影响

采用内皮素-1(ET-1 0.1 μmol·L^-1)建立培养的血管平滑肌细胞增殖模型，用［³H］胸腺嘧啶核苷(［³H］TdR)参入法, 流式细胞术, 免疫细胞化学及Northern blot方法, 观察了1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙氨基)丙烷盐酸盐(DDPH 0.1 μmol·L^-1)对血管平滑肌细胞增殖的作用及对原癌基因及抑癌基因的影响. 结果发现: DDPH能逆转ET-1所致［³H］TdR参入量增多, 阻止血管平滑肌细胞由静止期 (G₀/G₁期)进入DNA合成期(S期)和有丝分裂期(G₂/M期), 并能逆转ET-1引起的c-fos, c-myc, c-sis原癌基因相关抗原及 mRNA表达增强, P53抑癌基因相关抗原及mRNA表达减弱. 提示DDPH能抑制血管平滑肌细胞增殖, 与癌基因调控的分子生物学机理有关.     

叶酸抑制同型半胱氨酸诱导大鼠血管平滑肌细胞增殖的研究

目的探讨叶酸抑制同型半胱氨酸致大鼠血管平滑肌细胞增殖的研究。方法培养大鼠胸主动脉血管平滑肌细胞(VSMC),流式细胞仪检测VSMC周期,[³H]TdR参入测定VSMC的DNA合成。结果同型半胱氨酸以剂量依赖关系使VSMC周期中的G₀/G₁期细胞比例明显减少,S期细胞比例显著增多,增加VSMC的[³H]TdR参入。叶酸可明显抑制同型半胱氨酸诱导的作用。结论同型半胱氨酸能诱导VSMC增殖,叶酸能抑制同型半胱氨酸诱导的VSMC增殖。     

1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙氨基)丙烷盐酸盐对内皮素促血管平滑肌细胞增殖及癌基因表达的影响

采用内皮素－１（ＥＴ－１０．１μｍｏｌ·Ｌ－１）建立培养的血管平滑肌细胞增殖模型，用［３Ｈ］胸腺嘧啶核苷（［３Ｈ］ＴｄＲ）参入法，流式细胞术，免疫细胞化学及Ｎｏｒｔｈｅｒｎｂｌｏｔ方法，观察了１－（２，６－二甲基苯氧基）－２－（３，４－二甲氧基苯乙氨基）丙烷盐酸盐（ＤＤＰＨ０．１μｍｏｌ·Ｌ－１）对血管平滑肌细胞增殖的作用及对原癌基因及抑癌基因的影响．结果发现：ＤＤＰＨ能逆转ＥＴ－１所致［３Ｈ］ＴｄＲ参入量增多，阻止血管平滑肌细胞由静止期（Ｇ０／Ｇ１期）进入ＤＮＡ合成期（Ｓ期）和有丝分裂期（Ｇ２／Ｍ期），并能逆转ＥＴ－１引起的ｃ－ｆｏｓ，ｃ－ｍｙｃ，ｃ－ｓｉｓ原癌基因相关抗原及ｍＲＮＡ表达增强，Ｐ５３抑癌基因相关抗原及ｍＲＮＡ表达减弱．提示ＤＤＰＨ能抑制血管平滑肌细胞增殖，与癌基因调控的分子生物学机理有关．     

丹参酮ⅡA对血管紧张肽Ⅱ诱导增殖的 大鼠血管平滑肌细胞中c-fos与c-myc的影响

［摘要］目的探讨丹参酮ⅡA对血管紧张肽Ⅱ（AngⅡ）诱导的大鼠血管平滑肌细胞（VSMC）增殖的影响及其机制。方法分离大鼠胸主动脉中层平滑肌，贴壁法培养平滑肌细胞，建立AngⅡ诱导的VSMC增殖模型；以四甲基偶氮唑蓝（MTT）法观察丹参酮ⅡA对VSMC增殖的影响；流式细胞仪检测药物对细胞周期的影响；应用免疫细胞化学方法观察原癌基因c fos和c myc表达水平的变化。结果成功建立AngⅡ诱导的VSMC增殖模型；随着丹参酮ⅡA浓度增加，VSMC增殖活性呈明显下降趋势（P＜0.05）；流式细胞术结果显示丹参酮ⅡA使VSMC G0/G1期比例升高（P＜0.01），S期比例下降（P＜0.01）;丹参酮ⅡA各组随着浓度的增加，VSMC中c fos和c myc表达水平显著下降（P＜0.05）。结论丹参酮ⅡA具有抑制血管平滑肌细胞增殖的作用，并呈浓度依赖性。其机制可能与丹参酮ⅡA下调VSMC中c fos及c myc表达水平有关。     

萘哌地尔衍生物YMⅢ抗AngⅡ诱导SHR血管平滑肌细胞增殖的作用

目的观察萘哌地尔衍生物YMⅢ对血管紧张Ⅱ(AngⅡ)诱导的自发性高血压大鼠(SHR)血管平滑肌细胞(VSMC)增殖的影响,并初探其作用机制。方法以组织块贴壁法培养SHR VSMC,应用MTT比色法、3[H]-TdR参入法、流式细胞技术、电镜技术和real time RT-PCR分别观察VSMC在AngⅡ刺激下的细胞增殖、DNA合成、细胞周期、细胞超微结构和Agt、c-myc基因表达的变化,及观察YMⅢ对上述指标的影响。结果 AngⅡ1μmol.L-1明显促进VSMC增殖和DNA合成;而YMⅢ0.01、0.05、0.10μmol.L-1可呈浓度依赖性地抑制AngⅡ所致VSMC增殖活性、DNA合成、细胞周期增殖指数的升高,改善细胞超微结构,并使AngⅡ升高的Agt、c-myc mRNA表达下调。结论 YMⅢ可明显抑制AngⅡ诱导的SHR VSMC增殖,作用机制可能与其抑制Agt、c-myc mRNA表达,从而抑制细胞DNA合成和细胞周期的进展有关。     

血小板源生生长因子刺激血管平滑肌细胞增殖及其分子机制

目的：探讨血小板源生生长因子（PDGF－BB）刺激血管平滑肌细胞（VSMC）增殖及其分子机制。方法：用Western Blot法测定p44/p42 CCDPK活性。[^3H]脱氧胸腺嘧啶核苷酸掺入测定VSMC DNA合成。原位杂交检测c-myc mRNA的表达。结果：PDGFBB诱导的磷酸化CCDPK蛋白表达和[^3H]脱氧胸腺嘧啶核苷酸掺入呈浓度依赖性,此作用可被PTK抑制剂Genistein,外钙络合剂依他酸和MEK抑制剂PD 98059抑制。PDGF－BB刺激可引起c-myc mRNA的明显表达,此作用可被PD 98059抑制。结论：PDGF－BB通过激活p44/p42 CCDPK,上调c-myc mRNA的表达从而促进VSMC增殖,其作用是由PTK和Ca^2 介导的。     

1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙胺基)丙烷盐酸盐对自发性高血压大鼠血管平滑肌细胞增殖及对PDGF-B,bFGF,c-sis,c-myc的影响

用氚 胸腺嘧啶核苷(³H-TdR)掺入法,电镜,免疫组化,原位杂交方法,在自发性高血压大鼠(SHR)观察了1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙胺基)丙烷盐酸盐(DDPH)对血管平滑肌细胞(VSMC)增殖的作用及对生长因子PDGF-B,bFGF及其相关癌基因c-sis与c-myc表达的影响。结果发现:DDPH在降低SHR血压同时,能减少肾动脉VSMC的线粒体,粗面内质网和³H-TdR掺入量,并能逆转VSMC增殖时PDGF-B,bFGF抗原及c-sis与c-mycmRNA的表达增强。提示:DDPH能抑制SHR的VSMC增殖,与生长因子及癌基因调控的分子生物学机制有关。     

Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats

Cultured vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR) show exaggerated growth compared with cells from Wistar-Kyoto (WKY) rats. Calcium antagonists have recently been reported to have an in vivo antiproliferative effect on hypertensive cardiovascular organs. We investigated the effects of the calcium antagonist cilnidipine that blocks both L- and N-type calcium channels on the growth of VSMC from SHR. Cilnidipine (1 and 10 microM) significantly inhibited basal DNA synthesis in VSMC from both rat strains; the inhibition was significantly larger in VSMC from SHR than in cells from WKY rats, and was significantly greater than effects of nifedipine. Cilnidipine (1 microM) significantly inhibited serum-stimulated DNA synthesis in VSMC from both rat strains. The inhibition was more marked in VSMC from SHR than in cells from WKY rats. Angiotensin II, platelet-derived growth factor (PDGF)-AA, and phorbol-12-myristate-13-acetate dose-dependently increased DNA synthesis in VSMC from SHR but not in cells from WKY rats. Cilnidipine (1 microM) significantly suppressed this increase in DNA synthesis in VSMC from SHR. Expression of basic fibroblast growth factor (bFGF), transforming growth factor-beta1, and PDGF A-chain mRNAs was markedly greater in VSMC from SHR than in cells from WKY rats. Cilnidipine (1 microM) significantly inhibited the expression of TGF-beta1 mRNA in VSMC from SHR but not in cells from WKY rats. These findings suggest that cilnidipine exerts its antiproliferative effects through the inhibition of DNA synthesis induced by growth-promoting factors and by inhibiting the expression of TGF-beta1 mRNA in VSMC from SHR.     

Hemin inhibits hypertensive rat vascular smooth muscle cell proliferation through regulation of cyclin D and p21

We tested the hypothesis that HO-1 (heme oxygenase-1) activity varied between vascular smooth muscle cells (VSMC) in spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. HO-1 levels were measured under baseline and hemin-stimulated conditions and cell proliferation was monitored. Basal HO-1 levels in untreated cells were lower in SHR compared to WKY rats. Treatment with hemin increased HO-1 mRNA and protein levels in the cells obtained from WKY rats compared to that of SHR rats. However, hemin-treatment showed a greater inhibitory effect on VSMC proliferation in SHR rats than in WKY rats. Tin protoporphyrin IX (SnPPIX) showed a greater reversal of the anti-proliferative effect of hemin on cells from SHR rats than WKY. Similarly, VSMC proliferation from SHR was significantly inhibited in VSMC transfected with the HO-1 gene. These inhibitory effects were associated with cell cycle arrest in the G1 phase. The level of cyclin D, and cyclin dependent kinase inhibitor p21 was higher in SHR cells progressing through the G1 phase. Treatment of the cells with hemin down-regulated the expression of cyclin D and up-regulated that of p21. These results indicate that hemin, an HO-1 inducer, may play a more critical role in VSMC proliferation in SHR than WKY.     

Etidronate influences growth and phenotype of rat vascular smooth muscle cells.

Bisphosphonates have been reported to exhibit antiarteriosclerotic and anticalcification effects. We investigated the effect of a bisphosphonate, etidronate, on growth and phenotype of vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR). Etidronate (10 microM) significantly decreased DNA synthesis evaluated by [3H]thymidine incorporation in VSMC cultured without serum, and 1 microM etidronate significantly inhibited DNA synthesis in the presence of 10% calf serum. Etidronate (10 microM) significantly inhibited VSMC proliferation after 72h incubation. Etidronate (100 microM) significantly increased the expression of SM22alpha mRNA and protein in VSMC, while 10 microM etidronate significantly decreased the expression of matrix Gla mRNA. These findings indicate that etidronate inhibits the exaggerated growth of VSMC from SHR, while altering their phenotype from synthetic to contractile one. These effects of etidronate may account for its antiarteriosclerotic action.     

OPC-13340, a new dihydropyridine calcium channel blocker attenuates rapid vascular smooth muscle cell growth in spontaneously hypertensive rats.

We investigated the mechanism of the antimitotic effects of calcium channel blockers in vascular smooth muscle cells (VSMC) from spontaneously hypertensive rats (SHR). VSMC from SHR exhibited rapid proliferation through a quick transition from the G0/G1 to the DNA synthetic (S) phase and from the S to the G2/mitotic (M) phase, whereas the DNA synthetic rate itself was equal to that of Wistar-Kyoto rats (WKY). OPC-13340, a new dihydropyridine calcium channel blocker, dose-dependently decreased incorporation of [3H]thymidine into the DNA fragments in randomly cycling VSMC in SHR. Cell cycle analysis showed that the rapid transition from the S to the G2/M period was restored by OPC-13340 to the control level in WKY, whereas the quick transition from G0/G1 to S was unaffected. This antimitotic effect of OPC-13340 was reflected by attenuation of enhanced cellular protein synthesis during the G2/M period. Protein synthesis in the G0/G1 period was not influenced by OPC-13340. Thus, these data indicate that the calcium channel blocker OPC-13340 mitigates the enhanced proliferation observed in randomly cycling VSMC from SHR and that this effect is primarily due to normalization of the premature mitosis during the G2/M period.     

亚硝基乙酰青霉胺抑制人血管平滑肌细胞增殖的实验研究

目的探讨亚硝基乙酰青霉胺对人血管平滑肌细胞(VSMC)增殖的抑制作用。方法将不同浓度的亚硝基乙酰青霉胺300、500、800、1000μmol/L作用于体外培养的血管平滑肌细胞(VSMC),采用氚-胸腺嘧啶核苷(3H-TdR)掺入的方法检测细胞的增殖。结果在500、800、1000μmol/L的亚硝基乙酰青霉胺作用下,VSMC的3H-TdR掺入量cpm分别为1096.33±85.60、852.00±57.80、693.00±49.60,均与对照组的1270.00±96.50有显著性差异(P<0.01),并表现为剂量依赖性(P<0.01)。结论亚硝基乙酰青霉胺能够抑制人VSMC的增殖,可能有防治经皮腔内冠状动脉成形术后再狭窄的作用。